{"id":"W4387882142","doi":"10.1016/j.annonc.2023.10.117","title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; American College of Radiology Imaging Network; Society for Immunotherapy of Cancer; Pfizer Japan; Genentech; Mirati Therapeutics; Jounce Therapeutics; Chugai Pharmaceutical; MSD K.K.; Jazz Pharmaceuticals; Eli Lilly Japan; ECOG-ACRIN Cancer Research Group; Janssen Biotech; Helsinn; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Janssen Research and Development; EMD Serono; International Association for the Study of Lung Cancer; Sanofi; Amgen; Pfizer","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Pemetrexed; Oncology; Chemotherapy regimen; Lung cancer; Hazard ratio; Osimertinib; Regimen; Progression-free survival; Phases of clinical research; Cancer; Cisplatin; Erlotinib; Epidermal growth factor receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002308398,0.0001782993,0.0004392857,0.00009283267,0.00006173489,0.000008793139,0.00007516012,0.00005776498,0.00002090695],"category_scores_gemma":[0.00008521603,0.00009916975,0.00004145613,0.0002576453,0.0001152579,0.00006507428,0.00004142772,0.000148165,0.000005389209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007736996,"about_ca_system_score_gemma":0.0004544403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001479182,"about_ca_topic_score_gemma":0.0001470017,"domain_scores_codex":[0.9986279,0.0001099515,0.0003811656,0.000388091,0.0002423886,0.0002504883],"domain_scores_gemma":[0.9989946,0.000223355,0.0001924933,0.0003501443,0.00008245584,0.0001568946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2744207,0.007906552,0.1477709,0.00005332194,0.0007548148,0.001069532,0.01530106,0.000046078,0.001708406,0.00001220515,0.001474682,0.5494817],"study_design_scores_gemma":[0.09542955,0.01480629,0.8767246,0.0005896676,0.0003265742,0.000006446307,0.001660765,0.0001631833,0.0009234059,0.00007549482,0.009115864,0.0001781437],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813094,0.0004689016,0.000002736387,0.01516981,0.00006185504,0.001854055,0.000140164,0.00004815807,0.0009449866],"genre_scores_gemma":[0.99537,0.0003857031,0.0001225526,0.0032899,0.00005954666,0.000351941,0.0001730418,0.00002744081,0.0002199178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7289537,"threshold_uncertainty_score":0.4044025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03675421611862686,"score_gpt":0.4300967680827514,"score_spread":0.3933425519641245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}